Climb Bio Inc., a clinical-stage biotechnology company, has announced significant regulatory milestones in their ongoing efforts to advance treatments for immune-mediated diseases. The company has achieved regulatory clearance to initiate the Phase 2 trial of budoprutug for Primary Membranous Nephropathy (pMN) and the Phase 1 trial of subcutaneous budoprutug in healthy volunteers. These trials are expected to commence shortly, marking a step forward in Climb Bio's pipeline development. Additionally, Climb Bio is preparing for an IND or CTA submission for IgA Nephropathy (IgAN) in the second half of 2025. These advancements underscore Climb Bio's commitment to bringing innovative treatments to patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.